J. Hural

发表

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.

Zoe Moodie, Yunda Huang, Steven G Self, 2006, Journal of immunological methods.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis

Donald K Carter, Holly Janes, Devan V Mehrotra, 2008, The Lancet.

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

Allan C. deCamp, J. Mullins, J. Kublin, 2021, The New England journal of medicine.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Allan C. deCamp, J. Kublin, J. Mascola, 2017, Statistical communications in infectious diseases.

Development of flow cytometry‐based assays to assess the ability of antibodies to bind to SARS‐CoV‐2‐infected and spike‐transfected cells and mediate NK cell degranulation

G. Ferrari, G. Gray, G. Tomaras, 2022, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature

S. Buchbinder, J. Thakar, P. Goepfert, 2020, Scientific Reports.

Identification of Naturally Processed CD4 T Cell Epitopes from the Prostate-Specific Antigen Kallikrein 4 Using Peptide-Based In Vitro Stimulation1

R. Henderson, M. Kalos, S. Steen, 2002, The Journal of Immunology.

Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults

W. Blattner, D. Weiner, S. Kalams, 2012, PloS one.

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period

D. Montefiori, S. Kalams, M. McElrath, 2019, The Journal of infectious diseases.

Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial

J. Kublin, N. Frahm, G. Pantaleo, 2019, Science Translational Medicine.

Speci ﬁ city and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modi ﬁ ed Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

S. Hammer, B. Moss, S. Buchbinder, 2014 .

A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.

J. Mullins, T. Hertz, J. Kublin, 2016, Vaccine.

An Intron Transcriptional Enhancer Element Regulates IL-4 Gene Locus Accessibility in Mast Cells1

G. Henkel, J. Hural, Melissa A Brown, 2000, The Journal of Immunology.

A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults

R. Malley, D. Goldblatt, D. Briles, 2019, The Pediatric infectious disease journal.

The estimation of dihydropteridine reductase in human blood cells.

J. Whiteley, J. Hural, S. Webber, 1988, Clinica chimica acta; international journal of clinical chemistry.

Vitro Stimulation Antigen Kallikrein 4 Using Peptide-Based In Cell Epitopes from the Prostate-Specific Identification of Naturally Processed CD 4

R. Henderson, M. Kalos, S. Steen, 2002 .

Nuclear factor of activated T cells is associated with a mast cell interleukin 4 transcription complex

G. Henkel, M. Brown, L. Timmerman, 1996, Molecular and cellular biology.

Achieving intracellular cytokine staining assay concordance on two continents to assess HIV vaccine‐induced T‐cell responses

M. McElrath, Yunda Huang, V. Voillet, 2022, Journal of leukocyte biology.

Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.

S. Buchbinder, F. Sinangil, D. Barouch, 2012, The Journal of infectious diseases.

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation

Lindsay N. Carpp, D. Montefiori, T. Wrin, 2021, medRxiv : the preprint server for health sciences.

Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

S. Buchbinder, M. McElrath, G. Nabel, 2012, PLoS ONE.

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination

S. Buchbinder, M. McElrath, G. Nabel, 2012, PloS one.

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

K. Mansfield, S. Buchbinder, M. Robb, 2011, Vaccine.

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis

J. Mascola, D. Montefiori, R. Coler, 2022, Research square.

Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.

S. Hammer, M. McElrath, I. Frank, 2021, The Journal of clinical investigation.

Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody

Allan C. deCamp, J. Mascola, P. Gilbert, 2021, Journal of acquired immune deficiency syndromes.

Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge

S. Hammer, M. McElrath, I. Frank, 2021 .

Functions of IL-4 and Control of Its Expression.

J. Hural, Melissa A Brown, 2017, Critical reviews in immunology.

HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.

H. Zinszner, R. Coombs, P. Fast, 2015, Vaccine.

Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants

Michael P. Busch, Eric Hunter, Robert J. O'Connell, 2014, Clinical and Vaccine Immunology.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

J. Mascola, D. Montefiori, R. Bailer, 2017, PLoS medicine.

Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories

S. Self, P. Kaleebu, R. Koup, 2010, PloS one.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Donald K Carter, Ian Frank, Beryl Koblin, 2013, The Journal of infectious diseases.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

S. Hammer, H. Liao, T. Hertz, 2016, The Journal of infectious diseases.

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Lindsay N. Carpp, Allan C. deCamp, J. Mullins, 2022, Nature Medicine.

Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.

Lindsay N. Carpp, J. Kublin, M. McElrath, 2022, The Journal of infectious diseases.

Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C gag Vaccine in Healthy HIV-1-Uninfected Adults

D. Burke, N. Russell, S. A. Abdool Karim, 2012, Clinical and Vaccine Immunology.

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders

Jerome H. Kim, J. Mullins, S. Self, 2015, Nature Medicine.

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

W. Blattner, D. Montefiori, S. Kalams, 2011, PloS one.

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults

M. Andrasik, J. Kublin, M. McElrath, 2021, The New England journal of medicine.

Regulates IL-4 Gene Locus Accessibility in An Intron Transcriptional Enhancer Element

Melissa A. Brown, G. Henkel, J. Hural, 2000 .

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings

J. Mascola, J. Ledgerwood, L. Corey, 2021, Journal of acquired immune deficiency syndromes.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa

J. Kublin, D. Montefiori, M. McElrath, 2019, Science Translational Medicine.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

S. Hammer, R. Gottardo, S. Buchbinder, 2017, The Journal of infectious diseases.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Holly Janes, David C Montefiori, Peter B Gilbert, 2013, The New England journal of medicine.

Genetic impact of vaccination on breakthrough HIV-1 sequences from the Step trial

Peter B. Gilbert, Ann Duerr, Lawrence Corey, 2011, Nature Medicine.

Functions of IL-4 and control of its expression.

J. Hural, M. Brown, M. Brown, 1997, Critical reviews in immunology.

Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials

Marcella Sarzotti-Kelsoe, T. Denny, Daniel A. Ozaki, 2009, PLoS medicine.

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

W. Blattner, B. Moss, D. Montefiori, 2011, The Journal of infectious diseases.

Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants

Allan C. deCamp, W. Blattner, S. Hammer, 2014, Clinical and Vaccine Immunology.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

S. Hammer, B. Moss, D. Montefiori, 2014, The Journal of infectious diseases.

Abstracts from the 4th Annual Student Medical Summit

Alisha, D. Ahern, J. Butler, 2021, BMC Proceedings.

Daily Vaginal Swabs and Mobile Phone Sex Report for Assessing HIV Virion Exposure Prospectively Among a Cohort of Young Sexually Active Women in South Africa (HVTN 915)

M. Andrasik, J. Kublin, M. McElrath, 2019, Journal of acquired immune deficiency syndromes.

Preliminary studies on the primary structure of rat liver dihydropteridine reductase.

J. Whiteley, J. Hural, S. Webber, 1987, Biochemical and biophysical research communications.

High Asymptomatic Carriage With the Omicron Variant in South Africa

J. Andriesen, N. Garrett, L. Bekker, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19

O. Hyrien, I. Frank, G. Tomaras, 2022, JCI insight.

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

D. Montefiori, M. McElrath, L. Corey, 2011, The Journal of infectious diseases.

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

H. Liao, B. Haynes, D. Montefiori, 2014, The Journal of clinical investigation.

The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection

D. Clifford, N. Frahm, J. McElrath, 2016, Journal of acquired immune deficiency syndromes.

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation

Lindsay N. Carpp, D. Montefiori, T. Wrin, 2021, medRxiv.

Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal.

M. McElrath, J. Hural, C. Cooper, 2014, Journal of immunological methods.

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants

J. Andriesen, Yunda Huang, G. Tomaras, 2023, PLOS global public health.

Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays.

R. Gelman, G. Ferrari, A. Weinberg, 2010, Journal of immunological methods.

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

J. Mascola, J. Ledgerwood, L. Corey, 2021, Journal of acquired immune deficiency syndromes.

Multiple forms of rat-liver dihydropteridine reductase identified by their differing isoelectric points.

J. Whiteley, J. Hural, S. Webber, 1986, Archives of biochemistry and biophysics.

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

Allan C. deCamp, J. Mullins, J. Weiner, 2023, EBioMedicine.

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials

Allan C. deCamp, Dylan H. Westfall, J. Mullins, 2023, PLoS pathogens.

Structural studies and isolation of cDNA clones providing the complete sequence of rat liver dihydropteridine reductase.

J. Hoch, M. Shahbaz, J. Whiteley, 1987, The Journal of biological chemistry.

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation

Lindsay N. Carpp, D. Montefiori, T. Wrin, 2021, Scientific Reports.

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial

Allan C. deCamp, Jerome H. Kim, J. Mullins, 2009, Retrovirology.

Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees

M. Seaman, R. Coombs, P. D’Souza, 2020, Open forum infectious diseases.

Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

Kwaku Poku Asante, D. Follmann, M. Robb, 2023, eClinicalMedicine.

Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge

M. McElrath, A. McDermott, J. Ledgerwood, 2021 .

Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal.

J. Hural, C. Cooper, C. Ducar, 2014, Journal of immunological methods.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

J. Kublin, J. Fuchs, N. Sardesai, 2013, The Journal of infectious diseases.

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

Allan C. deCamp, J. Mullins, J. Weiner, 2023, EBioMedicine.

Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial

Allan C. deCamp, N. Frahm, A. Fiore-Gartland, 2024, EBioMedicine.